Cargando…

Relapses in Patients With Giant Cell Arteritis: Prevalence, Characteristics, and Associated Clinical Findings in a Longitudinally Followed Cohort of 106 Patients

Giant cell arteritis (GCA) is a relapsing disease. However, the nature, chronology, therapeutic impact, and clinical consequences of relapses have been scarcely addressed. We conducted the present study to investigate the prevalence, timing, and characteristics of relapses in patients with GCA and t...

Descripción completa

Detalles Bibliográficos
Autores principales: Alba, Marco A., García-Martínez, Ana, Prieto-González, Sergio, Tavera-Bahillo, Itziar, Corbera-Bellalta, Marc, Planas-Rigol, Ester, Espígol-Frigolé, Georgina, Butjosa, Montserrat, Hernández-Rodríguez, José, Cid, Maria C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4602452/
https://www.ncbi.nlm.nih.gov/pubmed/25181312
http://dx.doi.org/10.1097/MD.0000000000000033
_version_ 1782394720917389312
author Alba, Marco A.
García-Martínez, Ana
Prieto-González, Sergio
Tavera-Bahillo, Itziar
Corbera-Bellalta, Marc
Planas-Rigol, Ester
Espígol-Frigolé, Georgina
Butjosa, Montserrat
Hernández-Rodríguez, José
Cid, Maria C.
author_facet Alba, Marco A.
García-Martínez, Ana
Prieto-González, Sergio
Tavera-Bahillo, Itziar
Corbera-Bellalta, Marc
Planas-Rigol, Ester
Espígol-Frigolé, Georgina
Butjosa, Montserrat
Hernández-Rodríguez, José
Cid, Maria C.
author_sort Alba, Marco A.
collection PubMed
description Giant cell arteritis (GCA) is a relapsing disease. However, the nature, chronology, therapeutic impact, and clinical consequences of relapses have been scarcely addressed. We conducted the present study to investigate the prevalence, timing, and characteristics of relapses in patients with GCA and to analyze whether a relapsing course is associated with disease-related complications, increased glucocorticoid (GC) doses, and GC-related adverse effects. The study cohort included 106 patients, longitudinally followed by the authors for 7.8 ± 3.3 years. Relapses were defined as reappearance of disease-related symptoms requiring treatment adjustment. Relapses were classified into 4 categories: polymyalgia rheumatica (PMR), cranial symptoms (including ischemic complications), systemic disease, or symptomatic large vessel involvement. Cumulated GC dose during the first year of treatment, time required to achieve a maintenance prednisone dose <10 mg/d (T10), <5 mg/d (T5), or complete prednisone discontinuation (T0), and GC-related side effects were recorded. Sixty-eight patients (64%) experienced at least 1 relapse, and 38 (36%) experienced 2 or more. First relapse consisted of PMR in 51%, cranial symptoms in 31%, and systemic complaints in 18%. Relapses appeared predominantly, but not exclusively, within the first 2 years of treatment, and only 1 patient developed visual loss. T10, T5, and T0 were significantly longer in patients with relapses than in patients without relapse (median, 40 vs 27 wk, p  < 0.0001; 163 vs 89.5 wk, p = 0.004; and 340 vs 190 wk, p = 0.001, respectively). Cumulated prednisone dose during the first year was significantly higher in relapsing patients (6.2 ± 1.7 g vs 5.4 ± 0.78 g, p = 0.015). Osteoporosis was more common in patients with relapses compared to those without (65% vs 32%, p = 0.001). In conclusion, the results of the present study provide evidence that a relapsing course is associated with higher and prolonged GC requirements and a higher frequency of osteoporosis in GCA.
format Online
Article
Text
id pubmed-4602452
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Wolters Kluwer Health
record_format MEDLINE/PubMed
spelling pubmed-46024522015-10-27 Relapses in Patients With Giant Cell Arteritis: Prevalence, Characteristics, and Associated Clinical Findings in a Longitudinally Followed Cohort of 106 Patients Alba, Marco A. García-Martínez, Ana Prieto-González, Sergio Tavera-Bahillo, Itziar Corbera-Bellalta, Marc Planas-Rigol, Ester Espígol-Frigolé, Georgina Butjosa, Montserrat Hernández-Rodríguez, José Cid, Maria C. Medicine (Baltimore) Article Giant cell arteritis (GCA) is a relapsing disease. However, the nature, chronology, therapeutic impact, and clinical consequences of relapses have been scarcely addressed. We conducted the present study to investigate the prevalence, timing, and characteristics of relapses in patients with GCA and to analyze whether a relapsing course is associated with disease-related complications, increased glucocorticoid (GC) doses, and GC-related adverse effects. The study cohort included 106 patients, longitudinally followed by the authors for 7.8 ± 3.3 years. Relapses were defined as reappearance of disease-related symptoms requiring treatment adjustment. Relapses were classified into 4 categories: polymyalgia rheumatica (PMR), cranial symptoms (including ischemic complications), systemic disease, or symptomatic large vessel involvement. Cumulated GC dose during the first year of treatment, time required to achieve a maintenance prednisone dose <10 mg/d (T10), <5 mg/d (T5), or complete prednisone discontinuation (T0), and GC-related side effects were recorded. Sixty-eight patients (64%) experienced at least 1 relapse, and 38 (36%) experienced 2 or more. First relapse consisted of PMR in 51%, cranial symptoms in 31%, and systemic complaints in 18%. Relapses appeared predominantly, but not exclusively, within the first 2 years of treatment, and only 1 patient developed visual loss. T10, T5, and T0 were significantly longer in patients with relapses than in patients without relapse (median, 40 vs 27 wk, p  < 0.0001; 163 vs 89.5 wk, p = 0.004; and 340 vs 190 wk, p = 0.001, respectively). Cumulated prednisone dose during the first year was significantly higher in relapsing patients (6.2 ± 1.7 g vs 5.4 ± 0.78 g, p = 0.015). Osteoporosis was more common in patients with relapses compared to those without (65% vs 32%, p = 0.001). In conclusion, the results of the present study provide evidence that a relapsing course is associated with higher and prolonged GC requirements and a higher frequency of osteoporosis in GCA. Wolters Kluwer Health 2014-07-02 /pmc/articles/PMC4602452/ /pubmed/25181312 http://dx.doi.org/10.1097/MD.0000000000000033 Text en © 2014 Wolters Kluwer Health | Lippincott Williams & Wilkins
spellingShingle Article
Alba, Marco A.
García-Martínez, Ana
Prieto-González, Sergio
Tavera-Bahillo, Itziar
Corbera-Bellalta, Marc
Planas-Rigol, Ester
Espígol-Frigolé, Georgina
Butjosa, Montserrat
Hernández-Rodríguez, José
Cid, Maria C.
Relapses in Patients With Giant Cell Arteritis: Prevalence, Characteristics, and Associated Clinical Findings in a Longitudinally Followed Cohort of 106 Patients
title Relapses in Patients With Giant Cell Arteritis: Prevalence, Characteristics, and Associated Clinical Findings in a Longitudinally Followed Cohort of 106 Patients
title_full Relapses in Patients With Giant Cell Arteritis: Prevalence, Characteristics, and Associated Clinical Findings in a Longitudinally Followed Cohort of 106 Patients
title_fullStr Relapses in Patients With Giant Cell Arteritis: Prevalence, Characteristics, and Associated Clinical Findings in a Longitudinally Followed Cohort of 106 Patients
title_full_unstemmed Relapses in Patients With Giant Cell Arteritis: Prevalence, Characteristics, and Associated Clinical Findings in a Longitudinally Followed Cohort of 106 Patients
title_short Relapses in Patients With Giant Cell Arteritis: Prevalence, Characteristics, and Associated Clinical Findings in a Longitudinally Followed Cohort of 106 Patients
title_sort relapses in patients with giant cell arteritis: prevalence, characteristics, and associated clinical findings in a longitudinally followed cohort of 106 patients
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4602452/
https://www.ncbi.nlm.nih.gov/pubmed/25181312
http://dx.doi.org/10.1097/MD.0000000000000033
work_keys_str_mv AT albamarcoa relapsesinpatientswithgiantcellarteritisprevalencecharacteristicsandassociatedclinicalfindingsinalongitudinallyfollowedcohortof106patients
AT garciamartinezana relapsesinpatientswithgiantcellarteritisprevalencecharacteristicsandassociatedclinicalfindingsinalongitudinallyfollowedcohortof106patients
AT prietogonzalezsergio relapsesinpatientswithgiantcellarteritisprevalencecharacteristicsandassociatedclinicalfindingsinalongitudinallyfollowedcohortof106patients
AT taverabahilloitziar relapsesinpatientswithgiantcellarteritisprevalencecharacteristicsandassociatedclinicalfindingsinalongitudinallyfollowedcohortof106patients
AT corberabellaltamarc relapsesinpatientswithgiantcellarteritisprevalencecharacteristicsandassociatedclinicalfindingsinalongitudinallyfollowedcohortof106patients
AT planasrigolester relapsesinpatientswithgiantcellarteritisprevalencecharacteristicsandassociatedclinicalfindingsinalongitudinallyfollowedcohortof106patients
AT espigolfrigolegeorgina relapsesinpatientswithgiantcellarteritisprevalencecharacteristicsandassociatedclinicalfindingsinalongitudinallyfollowedcohortof106patients
AT butjosamontserrat relapsesinpatientswithgiantcellarteritisprevalencecharacteristicsandassociatedclinicalfindingsinalongitudinallyfollowedcohortof106patients
AT hernandezrodriguezjose relapsesinpatientswithgiantcellarteritisprevalencecharacteristicsandassociatedclinicalfindingsinalongitudinallyfollowedcohortof106patients
AT cidmariac relapsesinpatientswithgiantcellarteritisprevalencecharacteristicsandassociatedclinicalfindingsinalongitudinallyfollowedcohortof106patients